June guidelines from medical associations set the first framework to prevent, diagnose, evaluate and manage cardiovascular-kidney-metabolic syndrome, a disorder formally recognized in 2023.
The guidance treats heart, kidney and metabolic conditions as interconnected rather than separate illnesses, aiming to improve coordinated screening and care for patients who often have multiple overlapping risks.
Kaiser Permanente researchers said decades of evidence helped shape the framework, including early-2000s findings linking reduced kidney function to heart failure, stroke and death, and newer data showing obesity rising faster over time.
More than 85% of Kaiser patients with high blood pressure can meet treatment targets under a multipronged program, evidence researchers say supports broader systematic management across CKM risk factors.
Future work will focus on better personalized risk prediction and matching therapies to different CKM stages and combinations of conditions.